Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | TYK2 | P29597 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951029 | 0.88 | F10 (0.37) | F10F2PLAT | |
| SCHEMBL950090 | 0.80 | RECQL (0.45) | F10F2SMN1; SMN2 | |
| SCHEMBL950618 | 0.78 | F10 (0.35) | F10F2JAK2JAK1TYK2 | |
| SCHEMBL950873 | 0.77 | F10 (0.35) | F10F2 | |
| SCHEMBL949125 | 0.75 | F10 (0.43) | F10F2JAK2JAK1JAK3 | |
| Hydrochloric Acid SCHEMBL947909 | 0.74 | F10 (0.43) | F10F2JAK2JAK1JAK3 | |
| SCHEMBL947603 | 0.73 | F10 (0.33) | F10F2 | |
| Hydrochloric Acid SCHEMBL947935 | 0.68 | F10 (0.38) | F10F2 | |
| SCHEMBL947564 | 0.67 | CHRM2 (0.45) | F10F2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3448545 | 0.67 | F10 (0.39) | F10F2JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | F10 545/4885F2 2/4885JAK2 106/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | F10 490/4885F2 1/4885JAK2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.